|
|
|
|
| LEADER |
01858nam a2200169Ia 4500 |
| 001 |
10.1038-s41598-022-15524-9 |
| 008 |
220718s2022 CNT 000 0 und d |
| 020 |
|
|
|a 20452322 (ISSN)
|
| 245 |
1 |
0 |
|a Extracellular vesicles deliver sodium iodide symporter protein and promote cancer cell radioiodine therapy
|
| 260 |
|
0 |
|b Nature Research
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1038/s41598-022-15524-9
|
| 520 |
3 |
|
|a Extracellular vesicles (EVs) are a promising carrier for various cargos with antitumor effects, but their capacity to transfer the ability to transport radioiodine for cancer theranostics remains unexplored. Herein, we tested the hypothesis that EVs can be loaded with the sodium iodide symporter (NIS) protein and efficiently deliver the payload to recipient cancer cells to facilitate radioiodine uptake. The results revealed that donor cells either transduced with an adenoviral vector for transient expression or engineered for stable overexpression secreted EVs that contained substantial amounts of NIS protein but not NIS mRNA. Huh7 liver cancer cells treated with EVs secreted from each of the donor cell types showed significantly increased plasma membrane NIS protein, indicating efficient payload delivery. Furthermore, intact function of the delivered NIS protein was confirmed by significantly increased radioiodine transport in recipient cancer cells that peaked at 48 h. Importantly, NIS protein delivered by EVs significantly enhanced the antitumor effects of 131I radiotherapy. These results reveal that EVs are a promising vehicle to deliver NIS protein to cancer cells in sufficient amounts for radioiodine-based theranostics. © 2022, The Author(s).
|
| 700 |
1 |
|
|a Jung, K.-H.
|e author
|
| 700 |
1 |
|
|a Lee, J.H.
|e author
|
| 700 |
1 |
|
|a Lee, K.-H.
|e author
|
| 700 |
1 |
|
|a Mina, K.
|e author
|
| 773 |
|
|
|t Scientific Reports
|
